Evidence map›Paper›PMID 37196027›Full record

ArticlePLoS pathogens2023

Identification of CDRH3 loops in the B cell receptor repertoire that can be engaged by candidate immunogens.

Olivia Swanson, Joshua S Martin Beem, Brianna Rhodes, Avivah Wang, Maggie Barr, Haiyan Chen, Robert Parks, Kevin O Saunders, Barton F Haynes, Kevin Wiehe and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. AI-Driven BCR Modeling for Precision Immunology.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Olivia SwansonDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0001-8162-8358
Joshua S Martin BeemDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Brianna RhodesDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Avivah WangDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Maggie BarrDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Haiyan ChenDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Robert ParksDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Kevin O SaundersDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Barton F HaynesDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Kevin WieheDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
Mihai L AzoiteiDuke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.ORCID 0009-0005-7198-1162
Duke University · US

Funding

Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
NIAID NIH HHS P01 AI131251NIAID NIH HHS UM1 AI144371
6 · The paper itself

Abstract

A major goal for the development of vaccines against rapidly mutating viruses, such as influenza or HIV, is to elicit antibodies with broad neutralization capacity. However, B cell precursors capable of maturing into broadly neutralizing antibodies (bnAbs) can be rare in the immune repertoire. Due to the stochastic nature of B cell receptor (BCR) rearrangement, a limited number of third heavy chain complementary determining region (CDRH3) sequences are identical between different individuals. Thus, in order to successfully engage broadly neutralizing antibody precursors that rely on their CDRH3 loop for antigen recognition, immunogens must be able to tolerate sequence diversity in the B cell receptor repertoire across an entire vaccinated population. Here, we present a combined experimental and computational approach to identify BCRs in the human repertoire with CDRH3 loops predicted to be engaged by a target immunogen. For a given antibody/antigen pair, deep mutational scanning was first used to measure the effect of CDRH3 loop substitution on binding. BCR sequences, isolated experimentally or generated in silico, were subsequently evaluated to identify CDRH3 loops expected to be bound by the candidate immunogen. We applied this method to characterize two HIV-1 germline-targeting immunogens and found differences in the frequencies with which they are expected to engage target B cells, thus illustrating how this approach can be used to evaluate candidate immunogens towards B cell precursors engagement and to inform immunogen optimization strategies for more effective vaccine design.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsAntibodies, NeutralizingB-LymphocytesBroadly Neutralizing AntibodiesHIV AntibodiesHumansReceptors, Antigen, B-CellAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesReceptors, Antigen, B-Cell

Identifiers

PMID37196027
PMCPMC10228794
OpenAlexW4376959371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.